Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How long does chlorpromazine last?

R B Lacoursiere, H E Spohn

    The Journal of Nervous and Mental Disease
    |October 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Chlorpromazine (CPZ) primarily offers pharmacological benefits for a few days post-discontinuation. While some patients experience lasting therapeutic effects for months, this may not be due to active CPZ levels.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    "Burnout" and substance user treatment: the phenomenon and the administrator-clinician's experience.

    Substance use & misuse·2002
    Same author

    A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders.

    Alcoholism, clinical and experimental research·1995
    Same author

    The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics.

    Brain and cognition·1993
    Same author

    Assessing need for extended psychiatric hospitalization.

    Comprehensive psychiatry·1992
    Same author

    Effects of extended hospitalization: a one-year follow-up study.

    Bulletin of the Menninger Clinic·1991
    Same author

    Outcome at discharge for patients in an ongoing follow-up study of hospital treatment.

    Hospital & community psychiatry·1990
    Same journal

    Efficacy and Safety of Aripiprazole in Children and Adolescents With Autism Spectrum Disorder: A Meta-Analysis.

    The Journal of nervous and mental disease·2026
    Same journal

    Metacognitive Interpersonal Group Therapy for Adolescents With Personality Disorders: Results From the METAMIND-A Pilot Randomized Controlled Trial.

    The Journal of nervous and mental disease·2026
    Same journal

    Activation Syndrome in Patients Diagnosed With Major Depressive Disorder for the First Time: The Role of Past Hypomania Symptoms and Atypical Depression as Risk Factors.

    The Journal of nervous and mental disease·2026
    Same journal

    Predicting Social Motivation and Interactions in Schizophrenia: An Ecological Momentary Assessment Study.

    The Journal of nervous and mental disease·2026
    Same journal

    Use of EQUATOR Network Templates in JNMD: The STROBE Guideline for Observational Studies.

    The Journal of nervous and mental disease·2026
    Same journal

    Mental Illness Attributions and Their Association With Psychotherapy Change Process Expectations.

    The Journal of nervous and mental disease·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Psychiatry
    • Clinical Pharmacology

    Background:

    • Schizophrenia treatment often involves long-term medication like chlorpromazine (CPZ).
    • Understanding CPZ's persistence after discontinuation is crucial for managing patient care and treatment duration.

    Purpose of the Study:

    • To determine the duration of chlorpromazine (CPZ) pharmacological action and therapeutic effects after drug cessation in schizophrenic patients.
    • To differentiate between the presence of active drug/metabolites and the persistence of clinical benefits.

    Main Methods:

    • Review of existing literature analyzing blood, urinary, and clinical data related to CPZ persistence.
    • Examination of pharmacokinetic data (half-life) and pharmacodynamic effects (clinical outcomes) post-discontinuation.

    Related Experiment Videos

    Main Results:

    • Plasma CPZ and metabolite half-life suggests clearance within a few days.
    • Urinary excretion of CPZ and metabolites detected for up to 18 days.
    • Clinical improvements persisted for months in some patients, while others showed deterioration within weeks.

    Conclusions:

    • Substantial pharmacological action of CPZ likely lasts only a few days after discontinuation.
    • Persistent clinical benefits in some patients may be independent of active CPZ levels.
    • Further research is needed on the long-term storage and potential activity of trace CPZ amounts.